SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Sjoberg Daniel)
 

Search: WFRF:(Sjoberg Daniel) > Properties of the 4...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004025naa a2200481 4500
001oai:lup.lub.lu.se:e8804fdc-15de-47fa-a16d-422c664e162d
003SwePub
008170216s2017 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/e8804fdc-15de-47fa-a16d-422c664e162d2 URI
024a https://doi.org/10.1016/j.juro.2016.09.0862 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Vickers, Andrew4 aut
2451 0a Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone : Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above
264 1b Ovid Technologies (Wolters Kluwer Health),c 2017
520 a Purpose: The 4-kallikrein panel, commercially available as the 4Kscore™, is a reflex test for prostate cancer early detection that has been extensively validated in multiple international cohorts. It has been suggested that use of such reflex tests be limited to those with prostate specific antigen less than 10 ng/ml and negative digital rectal examination. We aimed to determine the value of the panel in men outside this "diagnostic gray zone.". Materials and Methods: We performed an individual patient data meta-analysis using data from prior studies on the 4-kallikrein panel. We calculated the properties of the panel for predicting high grade (Gleason 7+) cancer in a subgroup of men with either positive digital rectal examination or prostate specific antigen 10 to 25 ng/ml. Results: A total 2,891 men from 8 cohorts were included. An important proportion of patients, including 32% in the United States validation study, had prostate specific antigen 10 to 25 ng/ml or a positive digital rectal examination. For men with prostate specific antigen 10 to 25 ng/ml the fixed-effects estimate for the discrimination of the kallikrein model was 0.84 vs 0.69 for the base model (difference 0.128, 95% CI 0.098-0.159). In the positive digital rectal examination group discrimination was 0.82 vs 0.72 (difference 0.092, 95% CI 0.069-0.115). Decision analysis showed a clinical net benefit for use of the panel in this subgroup with a reduction in biopsy rates of about 20% and only a small number of high grade cancers missed, fewer than 3% of those not biopsied. Conclusion: The use of the kallikrein panel in men with a positive digital rectal examination or prostate specific antigen 10 to 25 ng/ml is justified.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Digital rectal examination
653 a Early detection of cancer
653 a Kallikreins
653 a Prostate-specific antigen
653 a Prostatic neoplasms
700a Vertosick, Emily A4 aut
700a Sjoberg, Daniel4 aut
700a Roobol, Monique J4 aut
700a Hamdy, Freddie4 aut
700a Neal, David E4 aut
700a Bjartell, Andersu Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urological cancer, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)kir-abj
700a Hugosson, Jonas4 aut
700a Donovan, Jenny L4 aut
700a Villers, Arnauld4 aut
700a Zappala, Stephen4 aut
700a Lilja, Hans4 aut
710a Urologisk cancerforskning, Malmöb Forskargrupper vid Lunds universitet4 org
773t Journal of Urologyd : Ovid Technologies (Wolters Kluwer Health)g 197, s. 607-613q 197<607-613x 0022-5347x 1527-3792
856u http://dx.doi.org/10.1016/j.juro.2016.09.086y FULLTEXT
856u https://europepmc.org/articles/pmc5315584?pdf=render
8564 8u https://lup.lub.lu.se/record/e8804fdc-15de-47fa-a16d-422c664e162d
8564 8u https://doi.org/10.1016/j.juro.2016.09.086

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view